Cytomegaloviruses and malignant brain tumors
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13899Keywords:
CMV containing preparations, glioblastomas, immunosuppression, immunotherapy, stem cells, сytomegalovirus (CMV)Abstract
Summary. The review analyzes in detail the data on cytomegalovirus (CMV) as the cause of the development of malignant brain tumors. The use of modern methods of immunohistochemistry and polymerase chain reaction makes it possible to detect both individual proteins and CMV genes in tumor tissue, while virus cannot be isolated from tumor tissue using classical virological methods. The paper discusses the theories of “hit-and-run” and “microinfections”, which explain the mechanism of action of CMV. The data on various molecular mechanisms of transformation of normal cells into tumor cells under the action of CMV are presented. The presence of CMV was shown not only in tumor cells, but also in neural stem cells, monocytes and macrophages. The possibility of using immunotherapy with T-lymphocytes and CMV-based dendritic cellular vaccines for the treatment of cancer patients is discussed in detail. Clinical data on their effectiveness are presented. Three possible mechanisms of the action of immunotherapeutic drugs containing CMV antigens are considered.
References
Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010; 10: 878–89.
Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 2010; 1: 8–16.
Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011; 157: 193–203.
Melnick M, Sedghizadeh PP, Allen CN. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol 2012; 92: 118–25.
Cobbs C, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer 2002; 62: 3347–50.
Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008; 116: 79–86.
Geder L, Sanford EJ, Rohner EJ, et al. Cytomegalovirus and cancer of the prostate: in vitro transformation of human cells. Cancer Treat Rep 1977; 61: 139–46.
Sanford EJ, Geder L, Laychock A, et al. Evidence for the association of cytomegalovirus with carcinoma of the prostate. J Urol 1977; 118: 789–92.
Demmler GJ. What is CMV? 2010 [webpage] cited; Available from: http://www.congenitalcmv.org/public.htm
Shen Y, Zhu H, Shenk T. Human cytomagalovirus IE1 and IE2 proteins are mutagenic and mediate “hit-and-run” oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc Natl Acad Sci USA 1997; 94: 3341–5.
Cinatl JJr, Vogel JU, Kotchetkov R, et al. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol Rev 2004; 28: 59–77.
Samanta M, Harkin L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003; 170: 998–1002.
Harkins L, Volk AL, Samanta M, et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002; 360: 1557–63.
Poltermann S, Schlehofer B, Steindorf K, et al. Lack of association of herpesviruses with brain tumors. J. Neurovirol 2006; 12: 90–9.
Lau S, Chen YY, Chen WG, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 2005; 18: 838–43.
Maussang D, Verzijl D, van Walsum M, et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 13068–73.
Slinger E, Maussang D, Schreiber A, et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010; 5: 58–64.
Sorg G, Stamminger T. Strong conservation of the constitutive activity of the IE1/2 transcriptional control region in wild-type strains of human cytomegalovirus. Gen Virol 1998; 79: 3039–47.
Cobbs CS, Soroceanu L, Denham S, et al. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res 2008; 68: 724–30.
Park JJ, Kim YE, Pham HT, et al. Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts. J Gen Virol 2007; 88: 3214–23.
Kluiver J, Kroesen B, Poppema S, et al. The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia 2006; 20: 1931–36.
Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009; 23: 1327–37.
Popkin DL, Watson MA, Karaskov E, et al. Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proc Natl Acad Sci USA 2003; 100: 14309–14.
Wehinger J, Gouilleux F, Groner B, et al. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996; 394: 365–70.
Spencer JV, Cadaoas J, Castillo PR, et al. Stimulation of B lymphocytes by cmvIL-10 but not LAcmvIL-10. Virology 2008; 374: 164–9.
Abou-Ghazal M, Yang W, Qiao W, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008; 14: 8228–35.
Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008; 6: 675–84.
Sherry MM, Reeves A, Wu JW. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27: 2383–92.
Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2006; 9: 67–8.
Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002; 76: 1285–92.
Mildner A, Schmidt H, Nitsche M, et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007; 10: 1544–53.
O’Farrell AM, Liu Y, Moore KW, et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and independent pathways. EMBO J 1998; 17: 1006–18.
Lin E, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66: 11238–46.
Alcantara Llaguno S, Chen J, Kwon CH, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009; 15: 45–56.
Luo MH, Schwartz PH, Fortunato EA. Neonatal neural progenitor cells and their neuronal and glial cell derivatives are fully permissive for human cytomegalovirus infection. J Virol 2008; 82: 9994–10007.
Odeberg J, Wolmer N, Falci S, et al. Late human cytomegalovirus (HCMV) proteins inhibit differentiation of human neural precursor cells into astrocytes. J Neurosci Res 2007; 85: 583–93.
Soroceanu L, Akhavan A, Cobbs C. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008; 455: 391–5.
Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol 2011; 103: 231–8.
Soderberg-Naucler C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008; 41: 218–23
Ranganathan PA, Clark P, Kuo J, et al. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 2012; 86: 854–64.
Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014; 74: 3466–76.
Ghazi A, Ashoori A, Hanley PJ, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother (Hagerstown, Md: 1997) 2012; 35: 159–168.
Rahbar A, Stragliotto G, Orrego A, et al. Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival: A case-control study. Herpesviridae 2012; 3: 3.
Rahman M, Dastmalchi E, Karachi A, Mitchel D. The role of CMV in glioblastoma and implications for immunotherapeutic strategies. Oncoimmunology 2019; 8: e1514921.
Peng C, Wang J, Tanksley JP, et al. Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience. Mol Clin Oncol 2016; 4: 154–8.
Reap EA, Suryadevara CM, Batich KA, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma. Cancer Res 2018; 78: 256–64.
Reap EA, Suryadevara CM, Batich KA, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 2017; 23: 1898–1909.
Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 2002; 99: 931–6.
Sanchez-Perez L, Choi BD, Reap EA, et al. BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer Immunol Immunother 2013; 62: 983–7.
Prins RM, Cloughesy TF, Liau LM. Induction of cytomegalovirus-specific anti-tumor immunity after autologous tumor lysate-pulsed dendritic cell vaccination in a patient with glioblastoma. New England J Med 2008; 359: 539–41.
Tietze JK, Wilkins DE, Sckisel GD, et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood 2012; 119: 3073–83.
Paijo J, Doring M, Spanier J, et al. GAS senses human cytomegalovirus and induces type I interferon responses in human monocyte-derived cells. PLoS Pathogens 2016; 12: e1005546.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
